Prof Joan Webster1,2,3, Prof Claire Rickard2, Dr Helen Healy1,3, Prof Jeffery Lipman1,3, Prof Adrian Esterman4, Prof Vineet Chopra5, Dame Prof Nicky Cullum6, Dr Li Zhang2, Prof Alexandra Mc Carthy7,8
1Royal Brisbane and Women’s Hospital, Herston, Australia, 2Menzies Health Institute, Griffith University, Nathan, Australia, 3University of Queensland, St Lucia, Australia, 4University of South Australia, Adelaide, Australia, 5University of Michigan, Health System, Ann Arbor, USA, 6University of Manchester, Manchester, England, 7Princess Alexandra Hospital, Woolloongabba, Australia, 8Queensland University of Technology, Kelvin Grove, Australia
Chlorhexidine discs have been shown to significantly reduce CLABSI but only in ICU populations; yet their use has been extrapolated to other clinical areas and to other devices such as PICCs, without evidence to support their effectiveness. Antimicrobial resistance to CHG has been demonstrated in in-vitro and is of theoretical concern in clinical settings. There have been no head-to-head comparisons between a CHG disc and any other antimicrobial disc so we have planned a 3-arm trial to test a chlorhexidine disc against a new disc containing polyhexanide biguanide (PHMB) and no disc. Populations other than ICU patients will be included.